dc.contributor.author | Mtewa, Andrew G. | |
dc.contributor.author | Amanjot, Annu | |
dc.contributor.author | Lampiao, Fanuel | |
dc.contributor.author | Okella, Hedmon | |
dc.contributor.author | Weisheit, Anke | |
dc.contributor.author | Tolo, Casim U. | |
dc.contributor.author | Ogwang, Patrick | |
dc.date.accessioned | 2023-01-20T07:09:23Z | |
dc.date.available | 2023-01-20T07:09:23Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Mtewa, Andrew G.et.al. (2022), SARS-CoV-2 vaccine development,;Coronavirus Drug Discovery | en_US |
dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/2720 | |
dc.description.abstract | Vaccine development is the entire process involved in the designing of a vaccine to the post release study period. Vaccines work against viruses, bacteria, fungi and parasites. The design in which an antiviral vaccine is made is in such a way that it boosts the natural human immune response to an
incoming virus by priming. In this way, the immune system is able to recognize antigens particular to the virus or for better vaccines, a particular strain of the virus [1]. The antigens have characteristic molecules that are found on the surface of the virus making it easily identifiable within a very short period. The response is that the immune system is ideally releasing immune cells that attack the viruses directly or by the release of antibodies Coronavirus. upon being triggered by the mere presence of the antigens. The antibodies get themselves attached to the virus and then immune cells engulf and destroy it. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Coronavirus Drug Discovery | en_US |
dc.subject | Vaccines | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Drugs | en_US |
dc.title | SARS-CoV-2 vaccine development | en_US |
dc.type | Book chapter | en_US |